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Human factor Xsanto is a form of coagulation 
factor X in which a mutation within  the  signal peptide 
region of the precursor protein has been correlated 
genetically  with a severe  deficiency of factor X in the 
affected individual. A point mutation results  in substi- 
tution of  Arg for Gly at the critical -3 position of the 
factor X signal peptide. To determine the biochemical 
effect of this mutation on the biosynthesis of factor X, 
the wild-type and mutant factor X cDNAs  were sub- 
cloned into a vector for transcription and translation 
in  vitro. Translation products of mRNAs encoding por- 
tions of both mutant and wild-type proteins were used 
in a systematic biochemical approach to evaluate  di- 
rectly the effect of the mutation on targeting, trans- 
port, and proteolytic processing in  vitro. The results 
show that targeting and transport of factor XsantoDomingo 
to the endoplasmic reticulum are functionally disso- 
ciated from the removal of the signal peptide by signal 
peptidase. Factor Xsanto D~~~~~~ is translocated into the 
endoplasmic reticulum but not processed by signal pep- 
tidase. Transient expression of the  wild-type and mu- 
tant factor X in human embryonic kidney 293 cells 
revealed apparently normal secretion of the glycosy- 
lated two-chain form of factor X but no secretion of 
factor Xsanto D ~ ~ ~ ~ ~ ~ .  Thus, the inability of signal pepti- 
dase to cleave factor Xsanto &,,,ingo is directly responsible 
for the absence of circulating factor X and leads to the 
bleeding diathesis in the affected individual. 
Secreted proteins are generally synthesized as precursors 
having NH2-terminal signal sequences which target  nascent 
secretory proteins to  the endoplasmic reticulum (ER)’ and 
are then removed by signal peptidase (1). Although signal 
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peptides that target  proteins to  the  ER have  widely variable 
amino acid sequences, they do have three common structural 
features: a  net positive charge at  the NH2  terminus;  a  central 
hydrophobic region; and  a carboxyl-terminal region with 
small, nonpolar amino acids at positions -1 and -3 (signal 
peptides are numbered negatively from the site of cleavage 
toward the NH, terminus of the precursor) preceding the 
cleavage site (2). A number of mutations within, or near, 
signal peptides have now been described that  alter  the proc- 
essing of human secretory proteins (3-6). Human interferon 
wl has  a signal peptide structure that presents two alternative 
cleavage sites for signal peptidase resulting in circulation of 
two forms of the protein that differ by two amino acids (7). 
Additionally, an insertion/deletion polymorphism has been 
identified in the signal peptide of the human apolipoprotein 
B gene that predicts two apolipoprotein B signal peptides: 
one that encodes a peptide of 27 residues and one that encodes 
a peptide of only 24 residues (8). The effect of this  mutation, 
if any, on secretion of apolipoprotein B has not been demon- 
strated. 
Antithrombin Dublin is an electrophoretically fast  variant 
of antithrombin that has been shown to be the result of a 
mutation at  the -3 position of the signal peptide in which 
Val is replaced by  Glu (4). Individuals expressing the mutation 
produce a form of antithrombin in which 2 amino acids 
normally found at the NH, terminus have been removed 
during  synthesis. It has been proposed that  the Val + Glu 
substitution redirects the site of cleavage by signal peptidase 
to a bond 2 amino acid residues toward the COOH terminus 
of the normal protein. This mutation appears to have no 
direct  correlation with any pathological condition (4). 
Similarly, albumin Redhill is an electrophoretically slow 
form of human serum albumin that contains two different 
mutations, one of which appears to cause signal peptidase to 
cleave at  an  alternate site (3). A substitution of Cys for Arg 
at  the penultimate position of the pro peptide (not  the signal, 
or pre, peptide) of preproalbumin apparently creates a  pre- 
ferred site for cleavage by signal peptidase. It was hypothe- 
sized, but  not proven, that  this mutation causes signal pepti- 
dase to preferentially cleave  following the newly introduced 
Cys, 5 residues into  the propeptide. Consequently, albumin 
Redhill circulates with an additional Arg residue at  the NH, 
terminus that would normally have been removed during 
processing of proalbumin. As with antithrombin Dublin, there 
is no disease state associated with the presence of albumin 
Redhill. 
Mutations in human signal peptides have been correlated 
with defective secretion and a consequent pathological state 
in only two reported cases: preproparathyroid hormone ( 5 ) ,  
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and coagulation factor Xsanto D,,,,,~,,~ (FXsd; Ref. 6). Substitu- 
tion of Arg for Cys within the hydrophobic core of prepropar- 
athyroid hormone causes a  disruption of the core that leads 
to impaired translocation  and/or processing of the nascent 
hormone. This  mutation is the  apparent cause of one form of 
familial isolated hypoparathyroidism ( 5 ) .  FXsd is a mutant 
form of human factor X in which a  point  mutation  results in 
the substitution of Arg for Gly at  the -3 position of the signal 
peptide (Fig. 1; Ref. 6). The patient bearing this mutation 
exhibits  a severe bleeding diathesis associated with less than 
1% FX enzymatic activity and less then 5% circulating FX 
protein. The intracellular consequences of this  mutation  are 
not immediately predictable since a  mutation within a signal 
peptide could potentially affect secretion at one or more 
stages. It could  block targeting of the nascent polypeptide to 
the  ER or it could block translocation  through the bilayer. A 
mutant signal peptide could also prevent cleavage  by signal 
peptidase or direct cleavage to a new site (9, 10). To distin- 
guish among these possibilities, a systematic approach using 
mRNAs encoding both mutant  and wild-type prepro-FX  pro- 
teins was  used t o  study the effect of the mutation on targeting, 
translocation,  and proteolytic processing by signal peptidase. 
The results precisely define the effect of the  Santo Doming0 
mutation and provide a model approach for analyzing the 
effects of signal peptide mutations on each stage of targeting, 
translocation,  and proteolytic processing of secretory precur- 
sor proteins. 
EXPERIMENTAL  PROCEDURES 
Synthesis of mRNA in Vitro-All cloning procedures used restric- 
tion enzymes and modifying enzymes purchased from Promega. The 
cDNAs of prepro-FXwt and prepro-FXsd (6) were subcloned into  the 
SacIIBarnHI sites of the plasmid pGEM-3Zf(+) (Promega) in the 
correct orientation for transcription by T7 RNA polymerase. Synthe- 
sis of mRNA in vitro was carried out on 2-5 pg of linearized DNA 
(specified in figure legends) for 1.5 h at 37 "C in the presence of 40 
mM Tris/HCl, pH  7.5,6 mM MgCl2, 2 mM spermidine, 10 mM NaCl, 
0.5 mM each rATP,  rCTP, rGTP,  and  rUTP,  and 40 units of T7 RNA 
polymerase (U. S. Biochemical Corp.). 
Polymerase Chain Reaction-Two synthetic oligonucleotides were 
prepared using an Applied Biosystems Model  380  DNA synthesizer. 
The sequence of the  T7 promoter of the pGEM-3Zf(+) plasmid is: 
5'-TAA TAC GAC TCA CTA TA-3' (oligonucleotide T7). The com- 
plementary region between bases 583 and 600 of FX cDNA is: 5'- 
CGC  GGA TCC CTA CCA TGT GAT GCT GTC AGG-3' (oligonu- 
cleotide X200). The underlined sequence is a  BamHI  site added at 
the 5'-end of oligonucleotide X200. Polymerase chain reaction am- 
plification (11) was performed in  a  final volume of 100 p1 containing 
1 pg of target DNA (plasmids pGEM-FXwt/FXsd), 10 mM Tris/HCl, 
pH 8.3, 50 mM KCI, 2.5 mM MgClz, 10 pg/ml gelatin, 200 p M  each 
dATP, dCTP,  dGTP,  and  dTTP, 1 pg  of each oligonucleotide, and 1 
unit of Taq DNA polymerase (AmpliTaq, Perkin-Elmer Cetus). The 
reaction mixtures were subjected to 20 cycles of denaturation at 94 "C 
for 90 s, annealing at 37 "C for 60 s, and primer extension at 72 "C 
for 70 s. The amplified DNA was recovered by phenol/chloroform 
extraction and ethanol precipitation and directly transcribed as de- 
scribed above. 
Cell-free Protein Synthesis-Translation of mRNA in  a cell-free 
system was performed, according to  the manufacturer's (Promega) 
procedure, in  rabbit reticulocyte lysate or wheat germ extract,  sup- 
plemented with 1 mCi/ml [35S]methionine, 1-2 mCi/ml [3H]isoleu- 
cine, or 1-2 mCi/ml [3H]alanine, as specified in the figure legends. 
Translation products were analyzed by SDS-PAGE (12) in the pres- 
ence of 2-mercaptoethanol followed by autoradiography of the dried 
gel using Kodak X-Omat AR films (Eastman Kodak). Enlightning 
(Du Pont-New England Nuclear) was used for fluorography of gels 
containing tritiated amino acids. 
Amino Acid Sequence Analysis-In preparation for amino acid 
sequence analysis, the proteins were separated by SDS-PAGE and 
transferred electrophoretically to polyvinylidene difluoride membrane 
(ProBlott, Applied Biosystems) using the transfer conditions as de- 
scribed (13). The dried blot was exposed to film for autoradiography 
and  the bands of interest were cut from the membrane and subjected 
to automated  Edman degradation in an Applied Biosystems Model 
475 Protein Sequencer. The content of radiolabel released by each 
cycle of Edman degradation was determined by liquid scintillation 
counting. 
Signal Peptidase Assay-A translocation-independent assay using 
full-length and truncated  prepro-FXwt/sd  proteins (produced by cell- 
free protein synthesis) as substrates for detergent-solubilized hen 
oviduct signal peptidase (HOSP) was  employed (14). In a total 
reaction volume of  20 pl, 2-4 pl of cell-free translation products were 
added to a buffer composed of 10 mM Tris/Cl,  pH  8, 250 mM NaCI, 
10% (w/v) glycerol, 1 mM MgCI2, 5 mM Chaps, 20 mM dithiothreitol, 
and 0.08  mg/ml phosphatidylcholine. Next, 5 pl of partially purified 
HOSP, diluted in the same buffer, were added and  the mixture was 
incubated at 28 "C for 60 min. Reactions were stopped by heating the 
samples at 100 "C for 3 min in the presence of an equal volume of 
SDS-PAGE sample buffer, then  the reaction products were separated 
by SDS-PAGE. The dried gel was subjected to autoradiography as 
described above. 
Assays for Translocation, Processing, and Membrane Association- 
The mRNAs coding for truncated prepro-FXwt/200 and prepro- 
FXsd/2OO were translated in a cell-free rabbit reticulocyte lysate 
system in the presence of  dog pancreas rough microsomes. The 
procedure followed was essentially as described (10) except that 
trypsin and chymotrypsin were used at  a final concentration of 50 
pg/ml each, instead of proteinase K. Carbonate  extraction of micro- 
somes was carried out as described (10) except that  the translation 
mixtures were not  treated with protease. 
Expression in Human Embryonic Kidney Cells-Full-length pre- 
pro-FX constructs were transfected into human embryonic kidney 
293 cells as described (6). Forty-eight hours following transfection, 
FIG. 1. The signal peptide se- 
quence of factor X. The amino acid 
sequences of the NHz-terminal prepro 
region of FXwt (29) and FXsd (6) are 
shown. The substitution of Arg for Gly 
at  the -3 position of the signal peptide 
of FXsd is highlighted in italic charac- 
ters. The actual  site of signal peptidase 
cleavage demonstrated in this report (see 
Fig. 4) is indicated by the arrow. Num- 
bers above the amino acids indicate their 
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the cells were pulse-labeled for 30 min with 0.5 mCi/ml [36S]methio- 
nine in Dulbecco’s modified Eagle’s mediump-12 medium in the 
presence of 10% (v/v) dialyzed fetal bovine serum and  then chased 
for 30 min, 2 h, and 6 h. A t  each time  point, the medium was collected 
and  the cells were  lysed in 50 mM Tris/HCl, pH 7.5, 150 mM NaCI, 
1% (v/v) Triton X-100,  0.5% (w/v) sodium deoxycholate, and 0.1% 
(w/v) SDS. Cell lysate fractions and culture media were immunopre- 
cipitated using rabbit anti-human FX polyclonal antibodies (Dako 
Corp., Santa Barbara, CA). To determine whether the translated 
translocated proteins were glycosylated, 5-pl aliquots of immunopre- 
cipitated FX  proteins were treated with peptide N-glycosidase F ( N -  
Glycanase, Genzyme  Corp., Cambridge, MA) as described (15). Pro- 
teins were separated by SDS-polyacrylamide gel electrophoresis and 
were detected by autoradiography. 
RESULTS 
cDNAs  encoding both prepro-FX wild-type (prepro-FXwt) 
and prepro-FXs,,, ~~~i~~~ (prepro-FXsd) were  subcloned into 
the vector pGEM-3Zf(+) to permit transcription of mRNA 
for translation in vitro (Fig.  2). Proteins produced by cell-free 
translation of mRNAs can be  analyzed in translocation-de- 
pendent assays that reconstitute the early steps of the secre- 
tory pathway that include membrane targeting, translocation, 
and proteolytic processing of nascent proteins (16). The same 
mRNAs can be used to prepare proteins for translocation- 
independent assays where the fully synthesized precursor 
proteins are substrates for purified signal peptidase (17). 
Incubation of full-length secretory precursor proteins with 
detergent-solubilized HOSP (14) results in cleavage of the 
signal peptide and the processed protein product can be 
detected because its smaller size  usually results in an increased 
mobility  compared to  the precursor when analyzed by SDS- 
PAGE and autoradiography. Transcription  and cell-free 
translation of the full-length prepro-FXwt and prepro-FXsd 
mRNAs  produced  polypeptides each with an apparent molec- 
ular mass of  64 kDa  based  on the mobility during SDS-PAGE 
(under reducing conditions) although the calculated molecular 
mass of the polypeptide chain is 54,377  Da. These translation 
products were immunoprecipitable with anti-human  FX  an- 
tibodies. Pro-FXwt, which was expected to result from re- 
moval of the 23-residue  signal peptide from full-length prepro- 
Eco RI 
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FXwt after  treatment with signal peptidase, was not clearly 
resolved  from the precursor by SDS-PAGE under reducing 
conditions (data not shown) so an alternate approach was 
taken. Since it has been  shown that signal peptidase normally 
cleaves nascent proteins during synthesis and translocation 
into  the  ER before the completion of the polypeptide chain 
(16), truncated versions of prepro-FX proteins were engi- 
neered  so that  the change in  molecular  weight resulting from 
removal of the signal peptide could be readily observed by 
SDS-PAGE analysis. 
The first  set of prepro-FX molecules with carboxyl-terminal 
deletions was created by transcription of prepro-FXwt and 
prepro-FXsd pGEM plasmids linearized by cleavage at  a 
unique PstI site within the coding  region to obtain mRNAs 
encoding the  first 127 amino acids of each protein (Fig. 2). 
Cell-free translation of these mRNAs yielded proteins mi- 
grating on SDS-PAGE with an  apparent molecular mass of 
18 kDa  (Fig. 3u, lunes 1 and 3). These truncated constructs 
were designated prepro-FXwt/l27 and prepro-FXsd/l27 for 
a 
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FIG. 2. Plasmid constructs of full-length and truncated 
forms  of  prepro-FXwt/sd. For the transcription of the full-length 
mRNAs, the plasmids were linearized with BumHI endonuclease 
which cleaves the plasmid downstream from the termination codon. 
To obtain the truncated prepro-FX/127, either wild-type or mutant, 
the plasmids were linearized with PstI endonuclease at  an internal 
site of the FX cDNA sequence following  codon  127. The construction 
of  prepro-FX/ZOO (wt or sd) was accomplished by polymerase chain 
reaction amplification of a 712-base pair  fragment from the plasmids, 
which includes the first 200 codons of the FX sequence, as described 
under “Experimental Procedures.” The location of the X200 primer 
is shown. 
R ” -  + + + + + +  
Pt0t.- - - - + + + +  
Det. - - - - - - + +  
FIG. 3. Assays for processing, translocation, and segrega- 
tion of prepro-FXwt/sd. u, translocation-independent processing 
assays (17) were performed on truncated prepro-FX/127 (wt and  sd) 
obtained by translation of mRNAs in  a wheat germ extract system 
supplemented with 1 mCi/ml [‘HILeu. Aliquots of the translation 
mixture were subsequently incubated with HOSP (+) or buffer only 
(-) as described under “Experimental Procedures.” Lanes I and 2 
show the translation  products from the wild-type constructs while 
lanes 3 and 4 show the  mutant proteins. b, for targeting, translocation, 
and segregation assays, the mRNAs coding for prepro-FX/200 (wt 
and  sd) were translated  in  a  rabbit reticulocyte lysate system supple- 
mented with 1 mCi/ml [%]Met in the presence (+) or absence (-) 
of  dog pancreas rough microsomes (RM).  After translation was  com- 
pleted, aliquots of the translation reactions were treated with a 
mixture of trypsin and chymotrypsin (Prot.) in the presence (+) or 
absence (-) of 1% (v/v) Triton X-100 (Det.) .  Lanes I ,  3, 5, and 7 
show prepro-FXwt/200; lanes 2 ,4 ,  6, and 8 show the  mutant protein, 
prepro-FXsd/200. 
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the normal and mutant proteins, respectively. The products 
of cell-free translation were then  treated with purified HOSP 
in a  translocation-independent assay to determine the ability 
of the peptidase to cleave each truncated precursor. HOSP 
cleaved prepro-FXwt/l27  to yield a  faster migrating protein 
band which was consistent with the removal of the signal 
peptide (Fig. 3a, lane 2 ) .  However, HOSP was unable to cleave 
prepro-FXsd/l27 (Fig. 3a, lane 4 )  which differs only by the 
presence of  Arg in place of Gly at  the -3 position before the 
predicted (see below) signal peptidase cleavage site. 
To directly determine the site of cleavage  by HOSP,  prepro- 
FXwt/127 labeled with either [3H]Ile or 13H]Ala  was digested 
with HOSP. The product of signal peptidase cleavage (Fig. 
3a, lane 2 )  was isolated and subjected to automated amino 
acid sequence analysis as described under “Experimental  Pro- 
cedures.” Sequence analysis of the signal peptidase cleavage 
product of [3H]Ile-prepr~-FXwt/127 released 3H at cycles 3 
and 11 (Fig. 4A), whereas the cleavage product of [3H]Ala- 
prepro-FXwt/l27 released 3H at cycle 8 (Fig. 4B). These 
results are consistent with cleavage after SerZ3 (Fig. 1). In 
later cycles of sequence analysis of this  protein,  a larger than 
usual increase in the carryover of amino acid residues from 
one cycle to  the next accounts for the peaks of radioactivity 
observed in cycles 12 (Fig. 4A) and 9 (Fig. 4B). Similar 
problems were encountered upon sequence analysis of the 
full-length prepro-FXwt (not shown) and are attributed to 
a 
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FIG. 4. Amino acid sequence analysis of the signal peptidase 
cleavage product of prepro-FXwt/l27. The product of SP cleav- 
age of prepro-FXwt/l27 was isolated as described under “Experimen- 
tal Procedures” and subjected to automated NHz-terminal amino acid 
sequence analysis. Panel A shows the result of Edman degradation of 
pro-FX labeled with [3H]Ile. Panel B shows the result of amino acid 
sequence analysis of pro-FX labeled with t3H]Ala. 
the difficulties encountered with the sequence analysis 
method. 
Having established that  the substitution of Arg for Gly 
blocked translocation-independent cleavage of prepro-FXsd 
by signal peptidase, we next investigated the effect of the 
mutation on the membrane targeting  and  translocation func- 
tions of its signal peptide. A second set of truncated molecules, 
designated prepro-FX/200, was prepared containing the first 
200 amino acids of prepro-FX (Fig. 2). Because there were no 
convenient restriction  sites  within the coding sequence that 
would yield a truncation mRNA of the desired size, the 
polymerase chain reaction (11) was  used.  Two synthetic oli- 
gonucleotides were designed to bracket a 712-base pair region 
including the  T7 RNA polymerase promoter region and  the 
first 200 amino acids of the prepro-FX coding sequence (see 
“Experimental  Procedures”).  These oligonucleotides were 
used as polymerase chain reaction primers to amplify  DNA 
from prepro-FXwt and prepro-FXsd pGEM plasmids. The 
DNA amplification products were then directly transcribed 
by T7 RNA polymerase and  the resulting mRNAs translated 
in the cell-free synthesis system. Translation of each trun- 
cated mRNA yielded a  protein migrating with an apparent 
molecular mass of 24 kDa (Fig. 3b, lanes I and 2). As with 
the 127-residue FX molecules, HOSP cleaved prepro-FXwt/ 
200 but  not prepro-FXsd/200 in translocation-independent 
assays (not  shown). 
Prepro-FX/200 mRNAs were next  translated in a cell-free 
protein synthesis system in the presence of dog pancreas 
rough microsomes (18) and  the locations of the protein prod- 
ucts were probed by addition of proteases. Proteins  that are 
targeted to  the ER and translocated to  the interior of the 
microsomal vesicles in these  translocation-dependent assays 
are protected from digestion by added proteolytic enzymes 
which cannot  enter the vesicles (19). Prepro-FXwt/200 was 
cleaved  by signal peptidase (Fig. 3b, lane 3 )  and the processed 
form was protected from proteolysis (Fig. 3b, lane 5). Although 
not cleaved by signal peptidase (Fig. 3b, lane 4 ) ,  prepro-FXsd/ 
200 was properly targeted to the microsomes because its 
unprocessed form was also protected from digestion by added 
proteases (Fig. 3b, lane 6) .  The protection from proteases 
observed in each case must have resulted from insertion of 
prepro-FXsd/200 and pro-FXwt/BOO into  the microsomes be- 
cause addition of detergent to  the reaction mixture allowed 
the proteases to penetrate the microsomes and destroy all 
protected FX molecules, establishing that they were not  in- 
herently stable to  the protease digestion (Fig. 3b, lanes 7 and 
8). 
Following cell-free synthesis of prepro-FX molecules in the 
presence of microsomes, the vesicles  were extracted with 0.1 
M Na2C03, pH 11.5, to determine whether the processed 
protein  products were integrated  into the lipid bilayer. Treat- 
ment of membrane vesicles at high pH solubilizes non-mem- 
brane  proteins  and leaves only integral membrane proteins 
associated with the sedimentable lipid bilayers (20). This 
technique revealed that the unprocessed prepro-FXsd/200 
and prepro-FXwt/ZOO were primarily associated with the pel- 
leted membranes (Fig. 5). In  contrast  to  the  uncleavedprepro- 
FXsd/200, the processed pro-FXwt/SOO  was released into  the 
supernatant upon treatment with carbonate,  further demon- 
strating  that  the cleaved form of the protein had been cor- 
rectly targeted to  the interior of the microsomes in a soluble 
state. We conclude that  the uncleaved prepro-FXsd/200 is 
translocated  into the microsomal vesicles  where it is protected 
from proteolysis and  remains anchored in the ER membrane 
via the uncleaved hydrophobic signal peptide. 
Less than 10% of prepro-FXwt/200 was observed associated 
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FIG. 5. Extraction of microsomes with carbonate. mRNAs 
coding  for prepro-FX/ZOO wild type ( WT)  and  Santo Domingo (SD) 
were translated  in a rabbit reticulocyte lysate  system  supplemented 
with 1 mCi/ml [“S]Met in the presence of dog pancreas rough 
microsomes. Following the  completion of translation,  the microsomes 
were treated with 0.1 M Na2C03 (Ref. 10). The resulting  pellet (Pel) 
and  supernatant (Sup)  fractions  from  each  carbonate  extraction were 
immunoprecipitated with anti-factor X then  examined by SDS-poly- 
acrylamide gel electrophoresis and  autoradiography. 
with the microsome pellet following carbonate  extraction (Fig. 
5). This precursor form must be exposed on the exterior 
surface of the microsomes because all uncleaved prepro- 
FXwt/2OO molecules were shown to be susceptible to  prote- 
olysis (Fig. 3b, lune 5 ) .  This result suggests that   at  least a 
small  proportion of correctly targeted precursor protein mol- 
ecules are present in a membrane-bound form that is not 
extractable by carbonate yet remains accessible to added 
proteinases. This may be the  result of an experimental artifact 
of the cell-free protein synthesis system in which the concen- 
tration of microsomes was limiting. Nevertheless, the effect 
of the  Santo Domingo mutation  on  targeting of factor X  is 
clear. In  the case of prepro-FXwt/200,  all translocated pro- 
teins,  as defined by protection from proteolysis, are cleaved 
by signal peptidase. This result stands in contrast to the 
mutant factor  X for which none of the  translocated prepro- 
FXsd/2OO molecules were cleaved. 
Experiments were next designed to compare the results 
obtained with the truncated proteins in a cell-free system 
with the effect of the  mutation  on  the secretion of the full- 
length proteins  transiently expressed  in  a  eukaryotic ell line. 
We  followed the  fate of pulse-labeled FX in transfected  hu- 
man embryonic kidney 293 cells (6), in  the cell media, and in 
the intracellular  fraction (Fig. 6). The mature,  two-chain form 
of FXwt (21) was secreted  beginning a t  30 min and reached a 
maximum level of secretion at  approximately 6 h (Fig. 6a). In 
contrast, FXsd was not detected  in the cell medium at  any 
time up to 24 h following the pulse of [35S]methionine (Fig. 
6b). In each case, FXwt  and  FXsd  proteins detected  in the 
intracellular  fraction were sensitive to digestion by N-glycan- 
ase  indicating that  they were glycosylated (Fig. 7) and  there- 
fore had reached the lumen of the ER. Cleavage by N- 
glycanase results in small, measurable increases in electro- 
phoretic mobility of the factor  X proteins  consistent with the 
removal of approximately  2 kDa of carbohydrate. These re- 
sults parallel those  obtained in  the cell-free system,  confirm 
the efficient translocation of prepro-FXsd into  the lumen of 
the  ER,  and show the absolute block of the secretion of the 
mutant protein. 
DISCUSSION 
Signal  peptides are recognized by several different proteins 
of the eukaryotic  translocation and processing apparatus  dur- 
ing the initial  stages of targeting  and  transport of nascent 
proteins into the ER (22). They are apparently recognized 
first by the 54-kDa subunit of the signal recognition particle 
which binds to the nascent protein and directs the entire 
synthetic complex to  the  ER  (23,24). Once bound to  the  ER, 




FIG. 6. Metabolic labeling of cells transfected with prepro- 
FXwt and with prepro-FXsd. Human  embryonic kidney 293 cells 
transfected  with  full-length  prepro-FX  constructs were  pulse-labeled 
for  30 min with [3sSS]Met, then  chased  for  0.5,2,  and 6 h. Cell lysates 
(C) and culture media (S )  were collected a t  each time point and 
immunoprecipitated  using  rabbit  anti-human FX polyclonal antibod- 
ies. Panel a shows  the  results for the wild-type FX protein  and panel 
b the  results for FXsd. 
Std Wt S D W t  SD 
N-Glycanase- 
97 
+ CHO- 69 
- CHo- 
46 
FIG. 7. Treatment of prepro-FX molecules with N-glycan- 
ase. Intracellular  forms of factor X proteins produced during  meta- 
bolic labeling in human embryonic kidney 293 cells were used to 
determine whether the proteins were glycosylated. The wild-type 
( Wt)  and  Santo Domingo (SD) factor X products  present immedi- 
ately following the chase with unlabeled methionine were either 
treated (+) or not treated (-) with N-glycanase to remove any 
attached carbohydrate. The products of the N-glycanase reaction 
were then  separated by SDS-polyacrylamide electrophoresis  and  de- 
tected by autoradiography. “C-Labeled  molecular  weight standards 
(Std) are  shown  in  the first lane. 
tulated  translocation  apparatus (25).  A 35-kDa ER membrane 
protein has been identified by photochemical  cross-linking as 
a putative signal sequence receptor  (26). Additional proteins 
yet to be identified may interact with the peptide as it is 
inserted into  the  translocation site.  Finally,  most ER signal 
peptides are proteolytically removed by signal  peptidase once 
the nascent protein has begun the process of transport or 
insertion into  the  ER (16). It is difficult to define  those  aspects 
of the signal  peptide that serve as recognition determinants 
for the various proteins  that  bind  them because the amino 
acid sequences of individual  signal  peptides  vary considerably 
(1, 27). Because the structural characteristics that mediate 
the specific interactions of signal  peptides  with the multiple 
components of the  translocation mechanism are  not yet well 
understood, the occurrence of a mutation within a signal 
peptide can have unpredictable consequences. The experi- 
ments described here provide an approach  using several es- 
tablished  techniques to dissect the early steps of the secretory 
pathway and identify those affected by mutations in the signal 
peptide region. The use of truncated mRNAs to produce 
5740 Factor X Signal  Peptide  Mutation  Blocks  Signal  Peptidase 
shorter precursor protein molecules is especially useful in 
those cases where the removal of the signal peptide from 
larger proteins is not easily demonstrated by SDS-PAGE 
methods. 
Since the interaction of the signal peptide with the signal 
recognition particle is the first  critical stage in targeting of 
the nascent polypeptide chain to  the  ER, some signal peptide 
mutants abrogate targeting  and cause the protein to be syn- 
thesized in the cytoplasm (1). Our experiments demonstrate 
that  the targeting  step is not blocked by the mutation in FXsd 
as the mutant protein is delivered to microsomal vesicles 
duringcell-free protein  synthesis (Fig. 3) and  to  the  ER during 
synthesis in intact cells (Fig. 6). These experiments demon- 
strate further that the mutation also does not block the 
process of translocation  into the lumen. It is the final step  in 
signal peptide function, its recognition and cleavage by signal 
peptidase, that is dramatically impaired in the case of FXsd 
as  a direct result of the substitution of Arg for Gly at  the -3 
position of the FXsd signal peptide. Both  truncated forms of 
prepro-FXwt analyzed in these experiments were  cleaved to 
pro-FX by detergent-solubilized signal peptidase in uitro. 
Under the same experimental conditions, cleavage of the 
truncated  prepro-FXsd molecules  was not observed. 
Sequence analysis of the signal peptidase cleavage product 
of prepro-FXwt provided the first  direct  demonstration of the 
site of processing of human prepro-FX. A preliminary report 
on the site of cleavage of the signal peptide for the bovine 
protein  has appeared (28) and  the site in human  prepro-FX 
has been correctly inferred from comparison of the gene 
organization of other vitamin K-dependent coagulation fac- 
tors (29, 30), but  this study is the first to demonstrate the site 
directly. Signal peptidase cleaved prepro-FX following SerZ3. 
Among the general structural  features  that  are present in 
all signal peptides, the amino acids close to  the cleavage site 
appear to have the strongest influence on the specificity of 
cleavage by signal peptidase (2,31). Signal peptides must have 
amino acids with small side chains at  the -1 and -3 sites 
immediately before the site of cleavage (2). Large aromatic, 
charged, or polar amino acid residues are not observed at 
these sites. The placement of Arg at  the critical -3 position 
of the prepro-FXsd  mutant signal peptide clearly interferes 
with cleavage. It should be noted that  this mutation did not 
induce a  shift in signal peptidase cleavage site, an effect that 
has been observed in  other cases. For example, substitution 
of Glu for Val at the -3 position of antithrombin Dublin 
results in redirection of signal peptidase cleavage to a new 
site 2 residues toward the COOH terminus of the protein (4). 
Similarly, albumin Redhill is another example in which a 
mutation appears to redirect signal peptidase cleavage to a 
new site  (3). Signal peptidase appears to have some degree of 
flexibility in  its selection of the site for cleavage if a suitable 
alternative site is present. In the case of prepro-FXsd, it 
appears that a suitable alternative cleavage site is not avail- 
able so the result of the mutation is to block  cleavage com- 
pletely. 
The results obtained in the cell-free system were further 
corroborated by the results of the  transient expression of the 
full-length prepro-FX wild-type and  Santo Domingo proteins 
in human embryonic kidney cells. The wild-type protein was 
processed and secreted efficiently in its two-chain zymogen 
form (21) while the  mutant  FX was never detectable in  the 
cell culture medium. Consistent with the observations i n  uitro, 
the protein detected in the intracellular compartment was 
glycosylated demonstrating that  the  mutant protein was in- 
deed translocated  into the  ER where glycosylation takes place. 
The finding that  the uncleaved signal peptide anchors prepro- 
FXsd/200 in the microsomal membrane suggests the possibil- 
ity that uncleaved prepro-FXsd remains inserted in the  ER 
in uiuo. As an abnormal ER membrane protein, it is likely 
that prepro-FXsd is retained in the ER. All membrane or 
soluble proteins that  are retained in the ER because of im- 
proper folding, failed oligomerization with required subunits, 
or  aberrant  post-translational processing, are eventually de- 
graded (32, 33). Sometimes this degradation process is quite 
rapid. In  the case of prepro-FXsd  transfected in human em- 
bryonic kidney cells, the protein is relatively stable although 
it is evident that  the protein is degraded slowly in these cells. 
The  patient expressing this  mutation did have a very low level 
of FX  antigen detectable in her blood  which  could represent 
a small portion of prepro-FXsd that escaped degradation. 
It is now clear that mutations in signal peptides of human 
secretory proteins  can have serious consequences. Although 
only two examples have been described thus  far which result 
in disease, preproparathyroid hormone (5) and factor X  Santo 
Domingo (6), additional examples will surely be  recognized in 
the future. As described here, a systematic approach to  the 
study of the specific effects of such mutations on the earliest 
stages of the biosynthesis of secretory or membrane proteins 
will lead to more complete understanding of the role of signal 
peptides and signal peptidase in human physiology. 
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